Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

This multicentre analysis of axitinib versus sunitinib used as first-line treatment for metastatic renal cell carcinoma (RCC) in 169 patients shows that compared with sunitinib, axitinib significantly prolonged cancer-specific survival and overall survival. Axitinib also had a safer adverse event profile compared to sunitinib as a first-line therapy for previously untreated metastatic RCC.

Read the abstract in UroToday here

Share this Post!


Related post

  TOP